ASCVD

AACE 2025 Updated Algorithm for Management of Dyslipidemia

This entry was posted in Cardiovascular Diseases and tagged ASCVD Dyslipidemia Update on by

The American Association of Clinical Endocrinology (AACE) has released its 2025 Consensus Statement and updated algorithm for the management of adults with dyslipidemia, offering concise visual guidance and tables to support clinical decision-making aimed at reducing atherosclerotic cardiovascular disease (ASCVD) and triglyceride-induced pancreatitis risk. Developed by an international multidisciplinary task […]

Obicetrapib Effective and Safe in Improving Lipids

This entry was posted in Cardiovascular Diseases and tagged ASCVD Lipids Obicetrapib on by

Two randomized, controlled trials evaluated the efficacy and safety of obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor, in lowering low-density lipoprotein (LDL) cholesterol in patients at high risk for atherosclerotic cardiovascular disease (ASCVD). Both trials show that obicetrapib is effective in reducing LDL cholesterol, with enhanced efficacy when […]